Xillix Technologies Corp (XLX.TO) Buy, Sell…

Xillix Technologies Corp (XLX.TO)

0.00

-0.00 (0.00%)

0 watching

BUY

Have a good technology and a well-run company. The question is, when do they get approval in the US for their commercialization of their ultraviolet scope.

DON'T BUY

In the bottom 20% of their database. Moving ahead with FDA testing. Still expected to lose six cents in 2004. Should see improvement in four months.

DON'T BUY

Essentially has no revenues. Highly speculative. Has always found it difficult to profitably navigate through the diagnostic arena.

BUY

A pretty solid company. Have completely turned around after a dispute with a partner a several months ago. Should be able to move up 20/25% a year.

DON'T BUY

Only likes companies that have good solid earnings. Too speculative.

DON'T BUY

Could be an interesting speculation in a year/18 months. Watching it.

BUY

Have an application before the FDA and approval is expected in May. Very speculative stock. Has pretty good opportunity because the technology is being used in Europe.

BUY ON WEAKNESS

Likes the company, but it has had a huge run. May be it would get it $ .10/15 cheaper.

BUY

An exciting stock. Have done a recent financing. Waiting for FDA approval. Getting geared up for sales in the states. Speculative.

BUY

Solved their financial problems. Good technology. Well-managed. Starting to get traction. Could be a takeout candidate.

BUY

Intrigued with the story. Going to do more work on it. Very speculative.

BUY

Strong CEO. Product has been approved in Europe. Have applied for FDA approval which is expected this spring. Once they get approval, expect they will hit the ground running. Speculative.

BUY

New endoscopy for lung cancer diagnostics approved in Europe and should have FDA approval next year. Earnings have grown from a loss of 0.08¢ to a loss of 0.03¢. Very exciting opportunities.

Showing 16 to 28 of 28 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Xillix Technologies Corp (XLX.TO)